Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Oil steadies as COVID-19-induced demand worries persist

Thu, 28th Jan 2021 05:31

* Delays with coronavirus vaccines in EU fuels demand
concerns

* China limits Lunar New Year trips as COVID cases rise

* Dollar gains on safe-haven bids, pressuring oil prices
(Updates prices)

By Ahmad Ghaddar

LONDON, Jan 28 (Reuters) - Oil steadied on Thursday after
early declines fuelled by delays to vaccine rollouts and fresh
travel curbs to prevent new coronavirus outbreaks.

Brent crude futures were up 8 cents, or 0.1%, at
$55.89 a barrel by 1331 GMT, having hit a session low of $55.31.

U.S. West Texas Intermediate (WTI) crude futures were
down 8 cents, or 0.2%, at $52.77 after dropping as low as
$52.22.

Oil prices were supported by data on Wednesday showing a
huge 10 million barrel decline in U.S. crude inventories last
week, which analysts said was because of a pick-up in U.S. crude
exports and a drop in imports.

But attention is returning to demand as contagious variants
drive a rise in coronavirus infections and a slower rollout of
vaccines in Europe and travel curbs in China are expected to
limit fuel consumption.

"Any sort of demand-related optimism remains on pause amid
the continued rise of new COVID-19 cases across key demand
centres and restricted mobility and public activity,"
consultants JBC Energy said.

Stricter vaccine checks by the European Union and delivery
hold-ups from AstraZeneca and Pfizer have slowed
the rollout of shots.

Adding to the bearishness over demand, China, the world's
second-largest oil consumer, faces a surge in coronavirus cases
and is seeking to limit travel as it heads into what is normally
the busiest travel season of the year, the Lunar New Year
holiday.

The Chinese Ministry of Transport has forecast the number of
trips that will be taken will rise 15% from last year, when the
virus was raging, but is still likely to be down 40% from 2019.

A strengthening dollar also weighed on prices. Buyers
using other currencies must pay more for dollar-denominated oil
when the greenback rises.

Data out later on Thursday is expected to show the economy
of the United States, the world's biggest oil user, contracted
in 2020 at its sharpest pace since 1946 because of the
pandemic.
(Additional reporting by Shu Zhang in Singapore and Sonali Paul
in Melbourne
Editing by Barbara Lewis and David Goodman
)

More News
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.